Aiforia is a public, Nasdaq-listed, global medical technology company aiming to escalate the efficiency and precision of medical image analysis beyond current capabilities. Aiforia provides healthcare professionals with deep learning AI and cloud-based image analysis solutions and services, empowering researchers in the identification of novel biomarkers of disease, supporting R&D scientists in speeding up time-to-market of novel drugs, and helping pathologists enhance the accuracy of cancer diagnostics. Today Aiforia has a global presence with over 5,000 users in over 50 countries, and an international multi-disciplinary team across Europe and in the United States. The Company is headquartered in Helsinki, Finland.
A portfolio of tools to increase productivity and improve diagnostic accuracy in pathology, including AI-supported diagnostics, intelligent visualization, QC, and automated pre- and post-analysis screening. We offer Clinical Suites for some of the world’s most prevalent cancers and have CE-IVD marking for AI models and our clinical viewer for prostate, lung, and breast cancer.
Aiforia's cloud-based AI software, Aiforia Create, allows pathologists and scientists to standardize, accelerate, and improve the efficiency of image analysis across a variety of preclinical applications from tumor grading, biomarker discovery, toxicological pathology studies and more.